MBX Biosciences (MBX) Change in Acquisitions & Divestments (2023 - 2026)

MBX Biosciences has disclosed Change in Acquisitions & Divestments across 4 years of filings, most recently posting $57.5 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $57.5 million, up 0.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $268.2 million (up 138.1% YoY), and the FY2025 annual result was $267.9 million, up 235.89% from the prior year.
• Change in Acquisitions & Divestments came in at $57.5 million for Q1 2026 at MBX Biosciences, down from $76.2 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $76.2 million in Q4 2025 to a low of $5.0 million in Q4 2023.
• The 4-year median for Change in Acquisitions & Divestments is $42.1 million (2024), against an average of $41.0 million.
• Across the five-year window, Change in Acquisitions & Divestments soared 786.33% in 2025 and grew 0.61% in 2026, its largest moves.
• MBX Biosciences' Change in Acquisitions & Divestments stood at $5.0 million in 2023, then surged by 305.0% to $20.2 million in 2024, then jumped by 276.54% to $76.2 million in 2025, then slipped by 24.59% to $57.5 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $57.5 million (Q1 2026), $76.2 million (Q4 2025), and $61.4 million (Q3 2025), per Business Quant data.